IPHA · Innate Pharma ADR
United States · RS rating 26 · As of 2026-11-03
| Price | 1.33 USD |
|---|---|
| 1-day change | -5.0% |
| RS rating (overall / 1M / 3M / 12M) | 26 / 26 / 26 / 30 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 19 / 7 / 19 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +47.5% |
| Market cap (USD) | $128.5M |